Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
Page 2

The organizers of the program hopes for the outcome of the project to have a substantial impact bioequivalence policy development for generic orally inhaled products.

Furthermore, the initiatives included under this funding opportunity announcement also intends to achieve the following objectives:

a) Develop a quality-by-design tool that could be utilized to improve the performance of orally inhaled drugs during the product development phase.

b) Determine accurate dose predictions.

c) Set clinical relevant aerodynamic particle size distribution specifications to ensure product quality, for these drug/device combination products.

To support these initiatives, the USFDA is ready to administer funds in the amount of $150,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The Department of Health and Human Services, the mother agency funding the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program, is the nation's leading agency for protecting the health of all Americans and providing fundamental human services to all.

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---

Minority-Based Community Clinical Oncology Program Groups
In line with this mission, the National Institutes of Health has recently collaborated with the National Cancer Institute (NCI) in an attempt to establish the Minority-Based Community Clinical Oncology Program Groups (MBCCOP).

---

Eradication of HIV from CNS Reservoirs: Implications for Therapeutics Grant Program
The National Institutes of Health has collaborated with The National Institute of Mental Health (NIMH), The National Institute of Neurological Disorders and Stroke (NINDS), and The National Institute of Allergy and Infectious Disease (NIAID) in an attempt to establish the Eradication of HIV from CNS Reservoirs: Implications for Therapeutics Grant Program.

---

Pilot Surveillance System for High Impact/Low Prevalence Congenital and Inherited Conditions Program
The Centers for Disease Control and Prevention has recently established the Pilot Surveillance System for High Impact/Low Prevalence Congenital and Inherited Conditions Program wherein it seeks to create and evaluate a surveillance system for congenital and inherited disease conditions.

---